mAb name  Target  IgG backbone  Fc modification  Effect on mAb  Therapy area  Most advanced development stage
Andecaliximab  Matrix Metalloproteinase 9 (MMP9)  IgG4  S228P  Stabilize core hinge  Oncology  Phase III
Anifrolumab  Interferon alpha/beta receptor 1  IgG1  L234F; L235E; P331S  Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding  Immunology  Phase III
Atezolizumab  PD‐L1  IgG1  Aglycosylated (N297A)  Ablate FcγR binding  Oncology  Marketed
Benralizumab  Interleukin 5  IgG1  Afucosylated  Selectively enhance FcγRIII interaction  Respiratory dermatology; ear nose throat disorders; gastrointestinal; hematology; immunology;  Marketed
Durvalumab  PD‐L1  IgG1  L234F; L235E; P331S  Mimic IgG4 hinge and its CH2 F/G loop; plus ablate FcγR binding  Oncology  Marketed
Evinacumab  Angiopoietin‐related protein 3  IgG4  S228P  Stabilize core hinge  Metabolic disorders  Phase III
Inebilizumab  CD19  IgG1  Afucosylated  Selectively enhance FcγRIII interaction  Central nervous system; oncology  Phase III
Ixekizumab  Interleukin 17A  IgG4  S228P  Stabilize core hinge  Dermatology; immunology; musculoskeletal disorders  Marketed
Margetuximab  HER2  IgG1  F243L; L235V; R292P; Y300L; P396L  Selectively enhance FcγRIII interaction  Oncology  Phase III
Mogamulizumab  C–C chemokine receptor type 4 (CCR4)  IgG1  Afucosylated  Selectively enhance FcγRIII interaction  Central nervous system; oncology  Marketed
Tafasitamab (MOR208 XmAb 5574)  CD19  IgG1  S239D; I332E  Selectively enhance FcγRIII interaction  Oncology  Phase III
Nivolumab  PD‐1  IgG4  S228P  Stabilize core hinge  Infectious disease; oncology  Marketed
Obinutuzumab  CD20  IgG1  Afucosylated  Selectively enhance FcγRIII interaction  Immunology; oncology  Marketed
Ocaratuzumab  CD20  IgG1  P247I; A339Q  Selectively enhance FcγRIII interaction  Oncology  Phase III
Pembrolizumab  PD‐1  IgG4  S228P  Stabilize core hinge  Infection; oncology  Marketed
Roledumab  Rhesus D  IgG1  Afucosylated  Selectively enhance FcγRIII interaction  Hematological disorders  Phase III
Spesolimab (BI‐655130)  IL‐36R  IgG1  L234A; L235A  Ablate FcγR binding  Gastrointestinal; immunology  Phase III
Teplizumab  CD3  IgG1  L234A; L235A  Ablate FcγR binding  Metabolic disorders  Phase II
Tislelizumab  PD‐1  IgG4  S228P; E233P; F234V; L235A; D265A; L309V; R409K  Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction  Oncology  Phase III
Toripalimab (JS 001)  PD‐1  IgG4  S228P  Stabilize core hinge  Oncology  Phase III
Ublituximab  CD20  IgG1  Afucosylated  Selectively enhance FcγRIII interaction  Central nervous system; oncology  Phase III